Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Imlifidase

Other · developed by Hansa Biopharma

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Imlifidase?

Imlifidase (Idefirix) is a drug studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Idefirix
Drug type
Other
Therapy area
Musculoskeletal
Developer
Hansa Biopharma AB
In trials of
SRPT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
UVJ7NL8S2P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06241950 Phase 1 Duchenne Muscular Dystrophy Terminated SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.